title: [A case of penicillin-resistant pneumococcal pneumonia and penicillin-binding proteins of the clinical isolates].
abstract: We experienced a case of a 68-year-old female with beta-lactam antibiotics including penicillin G (PCG) resistant pneumococcal pneumonia, leading to death during the treatment with ceftizoxime (CZX). We reported the clinical course and the mechanism of resistance of isolated bacteria. The present case is the first in Japan. Minimum inhibitory concentration (MIC) against Streptococcus pneumoniae 88031 isolated from the present case was 1.56 micrograms/ml in PCG and 6.25 micrograms/ml in CZX, showing PCG resistance. The isolate was no beta-lactamase production and serotype 23. The drug susceptibility in 34 strains of S. pneumoniae which were isolated as causative organism of respiratory infection in our department in 1988 was studied. PCG high resistant strain (PCG MIC greater than 1.56 micrograms/ml) was only observed in the isolated strain in the present case and PCG low sensitive strains (PCG MIC = 0.1-1.0 micrograms/ml) were observed in 3 strains (8.8%). The CZX resistance was observed only in the present case. The detection of penicillin-binding protein (PBP) and binding affinity of beta-lactam antibiotics were studied using PCG sensitive strain, S. pneumoniae type I (preserved strain PCG MIC = 0.05 micrograms/ml, CZX MIC = 0.1 micrograms/ml, CMX MIC = 0.025 micrograms/ml) and PCG resistant strain, S. pneumoniae 88031. The result obtained showed that PBP1a, detected in sensitive strain type I, was not detected in resistant strain 88031 and PBP1b was increased. The binding of 14C-PCG of PCG resistant strain to PBP1b showed lower affinity for CZX and CMX than PCG sensitive strain.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Second Department of Internal Medicine, Medical College of Oita.
authors.forename: H
authors.initials: H
authors.lastname: Shigeno
authors.forename: T
authors.initials: T
authors.lastname: Yamasaki
authors.forename: H
authors.initials: H
authors.lastname: Nagai
authors.forename: Y
authors.initials: Y
authors.lastname: Goto
authors.forename: T
authors.initials: T
authors.lastname: Tashiro
authors.forename: M
authors.initials: M
authors.lastname: Nasu
authors.forename: Y
authors.initials: Y
authors.lastname: Noji
authors.forename: K
authors.initials: K
authors.lastname: Okonogi
mesh_terms: D000368:Aged; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001426:Bacterial Proteins; D002352:Carrier Proteins / Q000032:analysis*; D015296:Ceftizoxime / Q000627:therapeutic use; D004352:Drug Resistance, Microbial; D005260:Female; D006602:Hexosyltransferases; D006801:Humans; D008826:Microbial Sensitivity Tests; D002267:Muramoylpentapeptide Carboxypeptidase / Q000032:analysis*; D046915:Penicillin-Binding Proteins; D010458:Peptidyl Transferases; D011018:Pneumonia, Pneumococcal / Q000382:microbiology*; D013296:Streptococcus pneumoniae / Q000737:chemistry / Q000187:drug effects* / Q000302:isolation & purification
chemical_list: D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D002352:Carrier Proteins; D046915:Penicillin-Binding Proteins; D015296:Ceftizoxime; D010458:Peptidyl Transferases; D006602:Hexosyltransferases; D002267:Muramoylpentapeptide Carboxypeptidase